Cigna (CI, $150.56) is "compelling" , says Citigroup analysts
According to a group of Citigroup analysts, Cigna is "one of the most compelling stocks and stories" they have seen across 20 years on the sell side.
The group of analysts feels that the health services company has the right goals coupled with a strong historical performance, a solid strategy, improved positioning, and a balanced growth outlook – while having a low valuation.
Analyst Ralph Giacobbe mentioned that Cigna is trading at a 27% discount to peers and 49% discount to the market.
Citigroup gave Cigna shares a “buy” rating. It set a $203 target price on the shares, which would be 11 times the 2020 estimate. The target indicates upside of 31% from Wednesday's close price.
However, Giacobbe did mention that the outlook is not without a few risks, such as a potential unexpected increase in healthcare-costs, heated competition from peers, the risks inherent in integrating Express Scripts, and general headline risks from the focus on drug pricing and the evolving pharmacy-benefit-manager model.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CI sees MACD Histogram just turned negative
CI saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 18, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 28 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 56%.
Technical Analysis (Indicators)
Bearish Trend Analysis
CI moved below its 50-day moving average on September 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CI crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 41%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
CI broke above its upper Bollinger Band on September 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 28 of 49 cases where CI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 57%.
The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on CI as a result. In 64 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
Following a +1.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where CI advanced for three days, in 224 of 355 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 161 of 272 cases where CI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.685) is normal, around the industry mean (3.247). P/E Ratio (11.242) is within average values for comparable stocks, (139.958). Projected Growth (PEG Ratio) (0.739) is also within normal values, averaging (0.786). CI has a moderately high Dividend Yield (0.023) as compared to the industry average of (0.009). P/S Ratio (0.264) is also within normal values, averaging (0.569).
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. CI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 58 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of health insurance services
Industry ManagedHealthCare
Advertisement